PRO DEX INC

Pro-Dex's Securities & Exchange Commission filings consistently disclose a single customer representing roughly 90% of revenue. While never explicitly named, industry analysis and surgical-robot supply chain mapping point to Stryker Corporation's Mako robotic-arm-assisted surgery platform as the ultimate end user. The relationship spans multiple years and product generations, making Pro-Dex effectively a dedicated supplier managing one extremely deep account. This concentration is the defining operational variable for any acquirer or equity holder.

The firm produces autoclavable powered surgical handpieces, torque-limiting drivers, and single-use rotary dissection tools for orthopedic and neurological procedures. The flagship product is a proprietary torque-limiting screwdriver used in robotic-assisted knee and hip replacement surgeries. Manufacturing covers multi-axis CNC machining, in-house brushless motor design, final assembly, and cleanroom packaging under FDA quality-system regulations.

In December 2023, San Francisco-based private equity firm Staple Street Capital completed a take-private acquisition of Pro-Dex for $112 million (per firm filings, December 2023). The transaction delisted PDEX from Nasdaq and took the company out of the public markets. Staple Street Capital's portfolio includes industrial and business-services companies, and the Pro-Dex acquisition adds medical-device contract manufacturing to that portfolio (per Staple Street Capital deal announcements, 2023).

No. Pro-Dex is a pure-play operating company — a contract manufacturer for the medical-device industry. Prior to the December 2023 take-private, it was a publicly traded entity on Nasdaq. It has never operated as a family office, held a portfolio of passive investments, or maintained a venture-capital or fund-commitment program. The firm's only assets are its Irvine manufacturing facility, inventory, and customer contracts.

Pro-Dex operates from a 75,000-square-foot facility in Irvine, California, with approximately 150 employees. The plant is FDA-registered and maintained to medical-device quality standards including ISO 13485. In-house capabilities cover multi-axis CNC milling, Swiss turning, cleanroom assembly, and testing. The facility's physical proximity to major orthopedic-device OEMs in Southern California is a non-trivial operational advantage that supports just-in-time sterile packaging logistics.

Staple Street Capital's $112 million acquisition of Pro-Dex takes a concentrated single-customer manufacturing asset private. The likely thesis hinges on (1) scaling the revenue base by expanding the product portfolio or customer set while maintaining the core robotic-surgery supply relationship, (2) extracting operational efficiencies now that quarterly reporting pressure is gone, and (3) positioning the company for a future strategic sale to a larger medical-device OEM consolidating its supply chain (per industry pattern analysis, public record).

It doesn't get diversified away — it gets priced in. Pro-Dex's board, management, and now its private equity owner have all accepted roughly 90% revenue concentration with one customer as the fundamental shape of the business. The mitigation is structural: extremely high switching costs for the customer, proprietary in-house motor designs that are qualified and validated as part of a regulated surgical system, and a history of multi-year purchase orders. An acquirer's due diligence would verify that the relationship is stickier than the concentration number suggests.